Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $299,092.39 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $74.34 on Monday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $29.90 and a 1 year high of $82.94. The firm has a market cap of $5.72 billion, a PE ratio of 76.64 and a beta of 0.05. The company has a 50 day simple moving average of $59.04 and a two-hundred day simple moving average of $51.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.38 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of KNSA. EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $31,000. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $34,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.38.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.